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Summary
    Serum of animals belonging to the Camelidae family (camels and llamas) contains fully active 
antibodies that are naturally devoid of light chains. Variable domains derived from heavy chain 
antibodies (hcAb) called VHHs or nanobodies™ can bind antigens as effectively as full-length 
antibodies and are easy to clone and express. Because of their potential, VHHs are being inten-
sively studied as potential therapeutic, diagnostic and imaging tools. The paper reviews the mo-
lecular background of heavy chain antibodies and describes methods of obtaining recombinant 
fragments of heavy chain antibodies as well as their therapeutic, diagnostic and other applications.
  Key words:	 heavy	chain	antibodies	•	VHH	•	Nanobody
Streszczenie
    Zwierzęta należące do rodziny Camelidae (wielbłądy i lamy) wytwarzają funkcjonalne przeciw-
ciała pozbawione lekkich łańcuchów, nazywane przeciwciałami ciężkołańcuchowymi (hcAb). 
Zmienne regiony tych przeciwciał (VHH lub Nanobody™) wykazują wysokie powinowactwo 
wobec antygenów, a jednocześnie mogą być wytwarzane z dużą wydajnością w systemach bak-
teryjnych. Ze względu na ich zalety w porównaniu z rekombinowanymi fragmentami klasycz-
nych przeciwciał, prowadzi się intensywne badania nad zastosowaniem VHH w terapii, diagno-
styce, obrazowaniu in vivo czy do oczyszczania białek.
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       -               -               -               -               -       IntroductIon
Discovery of the technique of monoclonal antibody pro-
duction triggered a revolution in biotechnology. The pro-
cedure, developed by Kohler and Milstein, is based on a 
chemical fusion of murine spleen cells that produce anti-
bodies with myeloma cells that give the new cells immor-
tality [46]. Monoclonal antibodies usually are monospe-
cific (they recognize only one type of antigen), and once 
cloned, they can be produced for ever. Therapeutic mo-
noclonal antibodies belong to the fastest-growing branch 
of biotechnology, but they have some limitations such as 
high cost of production in eukaryotic systems and large 
size that may disturb efficient tissue penetration. A solu-
tion for these problems can be obtaining Fab fragments, 
since they are three times smaller than full-size antibodies 
and can be expressed in a bacterial system. However, sin-
ce Fab fragments are heterodimers consisting of variable 
regions of heavy and light chains linked by disulfide brid-
ges, their cloning may encounter several difficulties and 
expression is not always efficient. Expression of single-cha-
in variable fragments (scFv) of antibody can also create 
problems, since such fragments are less soluble and they 
require a linker to keep both domains together (Fig. 1). In 
addition, scFv usually have lower affinity than Fab frag-
ments or antibodies and show a tendency to aggregate [87].
A sensible approach to avoid such problems is expres-
sion of functional fragments of heavy chain antibodies 
(hcAb), which are present in serum of animals belonging 
to the Camelidae family. Variable regions of heavy chain 
antibodies called VHHs or nanobodiesTM consist of sin-
gle polypeptide chains and have the following advantages 
over fragments of full-size antibodies and their fragments: 
easy, one-step cloning, small size that enables efficient pe-
netration of tissues, and high efficiency of expression of 
relatively stable protein in bacteria [13,54].
FamIly oF camelIdae
The Camelidae family (order: Artiodactyla) consists of six 
species: dromedary (Camelus dromedarius), Bactrian ca-
mel (Camelus bactrianus), llama (Lama glama), guanaco 
(Lama guanicoe), alpaca (Lama pacos) and vicuna (Lama 
vicugna). Animals belonging to this family are well ada-
pted to live in demanding environments such as deserts 
or high altitudes. They can lose water up to 30% of body 
mass, while for other mammals losing 12% is lethal. The 
high tolerance for dehydration is possible due to their abi-
lity to regulate body temperature, which allows them to 
decrease transpiration, and elliptic erythrocytes that are 
resistant to changes of ionic strength [60].
1. Structure and Sequence oF camel heavy chaIn antIbodIeS
Camel heavy chain antibodies were discovered by Ungar-
Waroni et al., who isolated low molecular weight Ig-like 
proteins from dromedary serum and showed their signi-
ficance in transmission of passive immunity from dam to 
calf by colostrum [79]. However, the detailed characteri-
zation and demonstration of potential usefulness of heavy 
chain antibodies stemmed from the work of the Hamers 
group in Brussels [33]. When analyzing antibodies isola-
ted from camel serum on protein A or protein G on SDS-
PAGE, they found that the unusual proteins belong to a new 
subclass of antibodies with lower molecular weight. In the 
absence of a reducing agent, a band of 94 kDa was visible 
on the gel in addition to the expected 150 kDa band, while 
in the presence of a reducing agent, only one 43 kDa band 
was found and no light chain was observed [33]. The au-
thors assumed that camel serum contains antibodies that 
are homodimers and consist of heavy chains only.
There are three subclasses of functional IgGs present in se-
rum of Camelidae: IgG1 is a heterodimer consisting of he-
avy and light chain homodimers, while IgG2 and IgG3 con-
sist only of heavy chains and thus are called heavy chain 
antibodies (hcAbs). Heavy chains of hcAbs consist of va-
riable domains called VHHs, followed by constant domains 
CH2 and CH3 (Fig. 1). Contrasting with regular antibody, 
there is no CH1 domain [55] and the hinge region linking 
VHH and CH2 regions is usually elongated, composed of 
repeated residues of proline, lysine, glutamine or glutamic 
acid. In consequence, the structure of the hinge region is 
more rigid and the distance between two binding domains 
is increased in comparison to regular IgGs [56]. Antigen-
binding fragments of regular antibodies can be expressed in 
the form of Fab or scFv fragments, and in both cases heavy 
and light chains have to be cloned separately. In contrast, the 
active antigen-binding fragment of heavy chain antibodies 
can be cloned and expressed in the form of VHH, which 
consists of only one polypeptide chain (Fig. 1).
Why are light chains not present in heavy chain antibo-
dies? In most mammalian cells, heavy and light chains 
combine together in the endoplasmic reticulum immedia-
tely after translation. The major ER protein involved in 
translocation, secretion, quality control and (if necessa-
ry) degradation of secreted proteins is called heavy cha-
in binding protein (BiP) [24,51]. A nascent heavy chain 
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       -               -               -               -               -       is bound by BiP immediately after translation and is reta-
ined until a light chain can replace BiP. If a light chain is 
absent, the heavy chain-BiP complex is bound by E3 ubi-
quitin ligase complex and transported across the membra-
ne to the proteasome [70] (Fig. 2A). BiP binds specifical-
ly to the CH1 segment of the heavy chain [36] and retains 
the heavy chain in the endoplasmic reticulum until BiP 
is exchanged for a light chain. Since CH1 regions are not 
present in antibodies belonging to the camel class IgG2 
and IgG3, such antibodies cannot be retained by BiP and 
are exported (Fig. 2B). CH1 regions are missing in matu-
re heavy chain antibodies because of the mutation G>A at 
the 3’-border between CH1 exon and the downstream in-
tron. The mutation does not allow the spliceosome to re-
cognize the splicing site, so the exon encoding CH1 is re-
moved together with introns (Fig. 3.) [57,86].
Fig. 1.   Schematic representation of regular 
(A) and heavy chain antibodies (B) and 
their fragments. The antigen binding 
site of a hcAb is composed of only one 
domain, called VHH, in contrast to 
regular antibodies in which that region 
is composed of VH and VL. The hcAbs also 
lack the CH1 domain of a heavy chain, 
and the hinge region is elongated in 
comparison to regular IgG. Fragments that 
can be derived from regular antibodies: 
Fab (C) and scFv (D) fragments and from 
heavy chain antibodies: VHH (E)
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Fig. 2.  Expression of heavy and light chains in endoplasmic reticulum (ER). Heavy and light chains are produced by ribosomes (R) and combine together 
in the lumen of the ER. (A) translation, secretion or degradation of conventional antibodies in the ER: the heavy chain is bound by BiP and released 
only when replaced by the light chain; if the light chain is not present, the heavy chain homodimer is bound by the E3 ubiquitin ligase complex 
and transported across the membrane to the proteasome. (B) translation and secretion of antibodies that lack CH1 domain in ER. BiP cannot 
bind hcAbs and the protein is secreted [36]
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Fig. 3.  Mechanism of removal of exon encoding 
CH1 during mRNA processing [57]. 
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       -               -               -               -               -       Variable domains of hcAbs contain several amino acid 
substitutions in comparison with heavy chains of regular 
antibodies. Most of these amino acid changes are found 
in the region that is engaged in hydrophobic interactions 
with a light chain: Val-37, Gly-44, Leu-45 and Trp-47 are 
usually replaced in hcAbs by Phe, Glu, Arg and Gly, re-
spectively (Fig. 4) [55]. Since a light chain is not present, 
these mutations provide higher solubility and stability to 
VHH (and exclude the possibility of pairing to a light cha-
in). Other mutations may occur within framework regions 
and can make VHHs even more stable.
There are several additional features that make VHHs dif-
ferent to regular antibodies and determine their unique pro-
perties. The CDR3 loops of hcAbs are usually longer than 
CDR3s in regular IgGs, and it is believed that such long lo-
ops may compensate for the smaller antigen binding site. 
Thus, the average length of CDR3 in heavy-chain antibo-
dy is 16-18 amino acids [55] in comparison to 9-12 amino 
acids in human antibody [88]. An extremely long CDR3 
with a 24 amino acid loop was found in a camel VHH that 
recognizes lysozyme: it was shown that the VHH can re-
ach the active site of an enzyme and act as its competiti-
ve inhibitor [19]. However, it should be noted that elon-
gated CDR3 regions are not always found in heavy chain 
antibodies, because CDR3s as short as 3 amino acids have 
also been described, particularly in llama VHHs [82]. It 
was also found that the CDR1 region can be elongated in 
VHHs and may show high variability [58,82].
Another distinctive feature of VHHs is a second disulfide 
bridge linking CDR1 and CDR3 (usually between amino 
acids 33 and 100e, Fig. 4.). The additional disulfide brid-
ge can stabilize the protein, but it may also enable forma-
tion of a new kind of loop that may recognize increased 
variety of epitopes [58].
It should be noted that heavy chain antibodies may also occur 
in humans or animals as a rare pathological event. Lack of 
a light chain is most often caused by mutations that lead to 
removal or shortening of the N-terminus of the heavy cha-
in, which makes joining of light and heavy chains impossi-
ble. However, such abnormal proteins do not behave as anti-
bodies (i.e. do not recognize a peculiar antigen) and tend to 
form aggregates that accumulate in different body compart-
ments, causing the syndrome of heavy chain disease [83].
2. heavy chaIn antIbodIeS In other SpecIeS
In addition to the members of the Camelidae family, heavy 
chain antibodies have been found in the adaptive immune 
system of cartilaginous fishes (sharks, rays and ratfish). 
Such antibodies, called immunoglobulin new antigen re-
ceptors (IgNARs), consist of five constant domains and one 
variable domain, which is responsible for antigen binding 
[30,66]. Interestingly, presence of the elongated CDR3 do-
main, increased occurrence of somatic mutations and an 
additional pair of cysteines that stabilize the structure are 
features that resemble antibodies found in animals belon-
ging to the Camelidae family [20,21,30].
The occurrence of hcAbs in evolutionarily distinct animal 
was reviewed by Flajnik et al. [25]. The authors suggest 
several possible explanations of this phenomenon: the li-
ght chain could have been used by a virus as a co-receptor 
for infection of B lymphocytes and that was the cause of 
light chain deletion. When the virus disappeared, the light 
chain could be used again; however, it was not restored to 
all kinds of IgGs. Alternatively, light chains could cause 
amyloidosis, and so their disappearance could serve as a 
positive evolutionary factor. However, the most probable 
possibility is that hcAbs have arisen as a means to reach 
less accessible epitopes.
3. recombInatIon and rearrangement
Shuffling of genes encoding VH and VL domains, which 
is one of the sources of imunoglobulin diversity, obviously 
does not exist in hcAbs. Nevertheless, the diversity of he-
avy chain antibodies is similar to the diversity of regular 
antibodies. Variable regions of antibodies belonging to all 
classes of Camelidae IgG are encoded by the same pool of 
D and J genes, but V gene segments that encode VHs and 
VHHs are usually distinct. Approximately 40 germline V 
genes used exclusively by heavy chain antibodies are present 
in the camel genome, and all are homologous to the genes 
of the human VH3 family [14]. Four additional germline 
genes used by both VHs and VHHs share homology with 
genes belonging to the human VH4 family [16]. It is note-
worthy that camel VHH fragments are more diverse than 
VH fragments [58]. The increased diversity of hcAbs and 
high number of off-sized VHHs in comparison with regu-
lar antibodies may be caused by the following mechanisms: 
•	 	 increased	number	of	hotspots	in	the	regions	that	usu-
ally do not show high hypervariability (e. g. elongated 
CDR1, aa 27–30 [58]);
•	 	 more	frequent	insertions	and	deletions	that	increase	va-
riability of CDR3 length [58];
•	 	 elongation	of	CDR3	that	may	be	caused	by	use	of	more	
than one D gene segments during V-D-J recombination, 
or enhanced activity of terminal deoxynucleotidyl trans-
ferase [56].
Fig. 4.   Schematic representation of differences 
in amino acid sequence between cDNA 
encoding variable regions of regular 
and heavy chain antibodies [13]. The 
critical amino acid substitutions in VHH 
are marked by lightning symbols. Thick 
black lines connecting FR1-FR3 and CDR1-
CDR3 represent disulfide bridges that 
stabilize the structure of the heavy chain
VH
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VHHs have the following advantages over murine antibo-
dies and their recombinant fragments: 
•	 	 VHHs	are	weakly	immunogenic	in	humans	because	genes	
encoding them share high sequence homology with ge-
nes belonging to the human VH families 3 and 4 [16,20];
•	 	 since	VHHs	consist	of	only	one	domain,	they	are	easy	to	
clone and can be expressed with high yields using dif-
ferent expression systems (described in section 7) [34];
•	 	 the	high	variability	of	length	and	sequence	of	VHHs	
makes them capable of recognizing a variety of epito-
pes, located not only on the surface of a protein [17], 
but also buried deep in the clefts [4]. VHHs have been 
shown to recognize a wide range of epitopes, ranging 
from small haptens [47,72,73] to binding sites of enzy-
mes [18,19];
•	 	 the	small	size	of	VHHs	allows	them	to	penetrate	tissu-
es, pass through barriers such as the blood-brain barrier 
and bind epitopes that cannot be reached by conventio-
nal antibodies [2,48];
•	 	 VHHs	show	high	solubility	and	stability	even	in	dena-
turing conditions or high temperatures [47].
5. methodS oF vhh preparatIon
Heavy chain antibodies can be produced in animals be-
longing to all species of the Camelidae family. Llamas are 
easier to raise and breed (because they are smaller), but 
camels have a better ratio of heavy chain antibodies to re-
gular antibodies [54]. VHHs are usually obtained from 
libraries that can be prepared from RNA of a naive or im-
munized animal (a general scheme of obtaining a heavy 
chain library is shown in Fig. 5). Usually, an animal is im-
munized with 1 mg or less of antigen (several antigens can 
be injected simultaneously) once a week for five consecu-
tive weeks (but obviously other regimens may be used). 
Complete Freund adjuvant may be used for the first injec-
tion and incomplete Freund adjuvant for the following in-
jections. Lymphocytes that are the source of mRNA can be 
isolated either from peripheral blood or from lymph nodes. 
Alternatively, libraries can be prepared as a synthetic pool 
obtained by grafting randomized CDR regions into heavy 
chain scaffolds [54,67]. The first method has an obvious 
advantage: VHHs that are matured in vivo usually have hi-
gher affinity and are more stable than those from non-im-
mune or synthetic pools. On the other hand, non-immune 
(from naive animal or synthetic) libraries may be the only 
solution if the antigen is toxic or cannot be used for immu-
nization. Such VHHs may have lower kinetic constants, 
but sometimes high affinity is not required. If a high affi-
nity is desired, one may use in vitro maturation (e.g. by er-
ror-prone PCR), but it can be a long and tedious process.
When a library of appropriate size is obtained, VHHs can 
be selected. The most frequently used method is solid-pha-
se phage display (Fig. 6), in which amplified cDNAs enco-
ding variable regions are expressed on the surface of fila-
mentous phages. Phages presenting variable regions that 
bind to the antigen are isolated by a procedure called pan-
ning and can be used in the next round of panning or to 
clone variable regions [13,85].
Fig. 5.  Procedure of obtaning a library of heavy chain antibody fragments. An animal is immunized with antigen, mRNA is isolated and cDNA encoding VHH 
fragments is cloned into the phage expression vector. Antigen-binding VHH fragments are then selected from the library by a panning procedure
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       -               -               -               -               -       There are several methods of expression of soluble VHH 
fragments. The first choice is usually production in 
Escherichia coli, where depending on the selected vec-
tor and bacterial strain, expressed protein can be direc-
ted to the periplasm or remain in the cytoplasm as a so-
luble product or inclusion bodies, with yields reaching 
5–10 mg of protein from 1 l of culture [27,32]. The other 
option is expression in yeast; yields of VHHs expressed in 
Saccharomyces cerevisiae can reach 250 mg of pure prote-
in secreted into one liter of culture [77]. The yields of pro-
tein can be even higher if Pichia pastoris yeast is selected 
for protein expression [62]. Production of VHHs is also 
possible in tobacco [43,63].
VHHs can be fused to various partners, either in order to 
increase their size or to confer new properties or effector 
functions. Thus the VHHs can be (Fig. 7):
•	 bivalent
  –  fused by a linker [8];
  –    fused to the IgG Fc domain, which can in addition 
confer antibody-dependent cell cytotoxicity [37];
•	 bispecific	[10,42];
Fig. 6.   Procedure of solid phase panning of 
proteins using phage display. The phages 
expressing VHH fragments on the surface 
are incubated with an antigen coated on 
a solid phase and the unbound phages 
are washed out. The phages bound to the 
antigen are eluted using high pH solution. 
Obtained phages can be used to infect 
bacteria for the next round of panning 
or to characterize the VHHs encoded by 
phages
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Fig. 7.   Different kinds of VHH multimerization 
or tagging
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•	 decavalent	[76];
•	 fused	to	an	enzyme	[12];
•	 	 fused	to	another	protein	to	increase	the	size	and	half-	
life, such as an Fc fragment [10].
6. applIcatIonS oF vhh FragmentS
The unique properties of VHHs make them useful in many 
applications, such as therapy, diagnostics and laboratory 
praxis. Some of the applications are described below and 
more are reviewed in [54,61,85].
6.1. VHHs in therapy
6.1.1. Anti-cancer therapy
Since it was demonstrated that VHHs can bind antigens 
on the surface of tumor cells and their immunogenicity is 
low [12], VHHs are under intensive scrutiny as potential 
therapeutic tools, and among the most studied are VHHs 
with potential anti-cancer activity. To date, VHHs recogni-
zing antigens that are expressed by cells of many types of 
cancer have been obtained, and many of them reveal pro-
spective therapeutic values.
A high-affinity VHH recognizing carcinoembryonic anti-
gen (CEA), a protein overexpressed in many types of tu-
mors, was used as a vehicle in the technique called anti-
body-dependent enzyme pro-drug therapy (ADEPT). The 
anti-CEA VHH was used as a transporter fused to b-lac-
tamase, an enzyme that can cleave a pro-drug of low to-
xicity into its toxic form (Fig. 8). The method was pro-
ved effective using a mouse model of adenocarcinoma: it 
was found that the tumor mass had decreased significan-
tly, while the toxicity of the drug was relatively low [11]. 
Another VHH with therapeutic potential is endoglin, a re-
ceptor involved in angiogenesis, which is up-regulated in 
cancer tissues. It was shown that the VHH recognizes the 
antigen with high affinity and can act as an anti-angioge-
nic agent by binding endoglin and inhibiting angiogene-
sis in the tumor [3].
A VHH recognizing Fcg receptor III was shown to activa-
te natural killer (NK) cells and induce production of in-
terferon g. The mono- and bispecific hcAb fragments ac-
tivated FcgRIII and recruited NK cells to the target site. 
Such a VHH, if fused to another VHH that recognizes a 
protein present on the surface of the tumor, may be used 
in anti-cancer therapy [5]. It was also shown that VHH 
recognizing integrin a3b1 (VLA3), an adhesion prote-
in involved in cancer metastasis, can decrease the meta-
static potential of malignant tumors. The same VHH can 
block cell-mediated adhesion by modulation of VLA3 
functions, so that VHH can be used to decrease tumor 
metastasis [31].
6.1.2. Hematological disorders
VHHs can also be used in other therapeutic applications. 
For example, advanced studies on therapeutic use of VHHs 
are focused on von Willebrand disease. Von Willebrand 
factor (VWF) is involved in the formation of blood clots by 
interactions with clotting factor VIII and platelets. There 
are two disorders involving VWF that may be treated with 
VHHs: vWFD type 2B that is caused by a decreased level 
of VWF and leads to elongated bleeding time, and throm-
botic thrombocytopenic purpura, which is caused by the 
lack of an enzyme that cleaves ultra-large VWF multimers 
which bind platelets. Such aggregates may accumulate in 
vessels, causing obstruction of blood flow. Hulestin et al. 
[40] obtained a VHH that binds to the active form of VWF 
and may be used as a diagnostic tool to detect VWF in se-
rum, since an increased level of active VWF is a key factor 
in both kinds of disease. Two VHHs recognizing VWF are 
currently undergoing clinical trials [69]. A VHH that pre-
vents platelet aggregation binds to ultra-large VWF mul-
timers and may be used to prevent spontaneous clotting in 
acute coronary syndrome and percutaneous coronary inte-
rvention [78,80]. The other VHH improves the time course 
of normalization of the platelet level in blood and prevents 
capture of platelets by VWF, so it may lead to improved 
treatment of von Willebrand disease type 2B in addition to 
the standard plasma-exchange therapy. Currently (March 
2012), both drugs are in phase II clinical trials.
Fig. 8.  Application of VHH in ADEPT therapy. VHH fused to an enzyme (green pacman) cleaves pro-drug (cephalosporin mustard marked as a bomb) 
into its active form phenylenediamine mustard (skull), causing decrease of tumor mass. Generation of a toxic pro-drug in the close vicinity of 
the tumor ensures high efficiency and low toxicity of ADEPT therapy (based on [11])
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It was shown that VHHs derived from an animal immuni-
zed with TNFa can be used to inhibit functions of TNFa 
in a murine model. Such VHHs may be a cheaper alter-
native to the currently available anti-TNFa drugs used in 
rheumatoid arthritis therapy [10]. It is noteworthy that an-
ti-TNFa VHH in its bivalent form (fused to a human Fc 
fragment) is now in the second phase of clinical trials. It 
was also shown that bacteria of a Lactococcus lactis   strain 
can be used as a carrier for VHHs recognizing TNFa: an-
tibody fragments were secreted by bacteria directly in the 
colon, acting as therapeutic agents for patients suffering 
from chronic colon inflammation [81]. The major advanta-
ge of such a strategy is that it may allow one to avoid pro-
teolysis of orally administered VHHs [34,35].
6.1.4. Toxins
Another application of VHHs is neutralization of toxins. It 
was shown that IgGs isolated from the serum of an immunized 
dromedary can neutralize toxins of the scorpion Androctonus 
australis [52]. VHHs recognizing the most important toxin 
components, AahII [1] and AahI’, have also been obtained 
[1,37]. Furthermore, it was shown that the bivalent VHHs 
consisting of two identical anti-AahI’ VHH domains linked 
together or bispecific VHHs containing anti-AahI’ and anti-
-AahII VHHs can neutralize scorpion toxins. The additional 
advantage of such constructs is higher molecular mass that 
increases their blood circulation time. Such bivalent or bispe-
cific antibody produced in bacteria can be a reliable alterna-
tive to currently used horse-derived Fab’2 fragments [38]. A 
VHH that inhibits enzymatic activity of botulinum neuroto-
xin has also been described, and it was suggested that it may 
be used to treat patients poisoned by botulinum toxin [9,23].
6.1.5. Infectious diseases
VHHs are also being tested in therapy of disease caused by 
protozoa, such as trypanosomiasis (e.g. sleeping sickness) 
caused by parasites from the Trypanosoma genus. The outer 
surface of the parasite is covered with hypervariable prote-
ins, so obtaining antibodies that recognize these proteins is 
difficult. The VHHs, however, due to their small size, can 
access more conserved epitopes that are located deeper un-
der the surface of the parasite. It was shown that a VHH lin-
ked to b-lactamase, which can convert a pro-drug to an ac-
tive drug, might be used in the therapy of sleeping sickness 
[75]. A therapy based on a VHH fused to the trypanolytic 
factor present in human serum was also proposed [4]. Finally, 
it was shown that a nanobody may be per se trypanolytic 
when interacting with the parasite, despite missing the Fc 
fragment (which mediates ADCC function) [74]. Another 
example of a VHH that can inhibit invasion of protozoa is a 
VHH recognizing the Duffy antigen receptor for chemokines 
(DARC) from human erythrocytes. It was shown that it can 
inhibit binding of Plasmodium vivax to red blood cells [71].
VHHs have been shown to inhibit bacterial and viral infec-
tions. For example, a VHH recognizing b-lactamase may in-
hibit enzyme function and may increase bacterial sensitivity 
to b-lactam antibiotics when administered together with an 
antibiotic [8]. VHHs recognizing proteins involved in HIV 
infections were shown to block HIV infection and thus such 
VHHs may be considered as prospective drugs. These prote-
ins are virus envelope protein gp120, which is involved in re-
cognition of CD4 antigen [26,45], and human CXCR4, which 
is a co-receptor for virus entry into CD4+ T-cells [44,45].
VHHs recognizing other viruses have also been obtained. 
For example, a VHH against capsid protein of hepatitis B 
virion, which is involved in virus secretion, was shown to 
bind to the virion protein in vitro and in vivo and to inhi-
bit release of the virus [68]. It was also shown that a VHH 
recognizing rotavirus can provide cheap and efficient pro-
tection to pigs against virus infections if secreted by or an-
chored to bacteria belonging to the Lactobacilli strains 
and added to chow fed to animals [59]. Recently, a VHH 
that recognizes native M2 channel protein from influenza 
A virion was shown to inhibit replication of influenza A 
viruses in vitro, block proton influx through M2 channels 
and to protect mice from lethal influenza virus challenge. 
Such broad-specificity VHH may provide potential protec-
tion against variants and subtypes of influenza A viruses 
[84]. A VHH that binds to H5 hemagglutinin was shown 
to reduce viral replication of H5N1 influenza virus in mice 
and significantly delay time to death [41].
VHHs recognizing the tail of infectious phages were also 
shown to protect Lactococcus bacteria, strains of which 
are important in the dairy industry, against infection by 
phages [15,49].
Finally, an unusual application of VHHs is anti-dandruff 
shampoo. Dolk’s group showed that it is possible to ob-
tain VHHs that are active even in a high concentration of 
surfactants. They obtained a VHH recognizing a surface 
protein of Malassezia furfur, a microorganism implicated 
in dandruff formation, and suggested that such an antibody 
may reduce the number of M. furfur and serve as a carrier 
of a therapeutic agent if used as a shampoo ingredient [22].
6.2. Applications of VHHs in diagnostics and 
biotechnology
6.2.1. Imaging
Due to their small size and high affinity, VHHs are being 
increasingly used in applications such as biotechnology and 
diagnostics. In particular, VHHs have all the properties of a 
perfect imaging tool because they can easily penetrate tis-
sues, accessing also cryptic antigens (e.g. located behind 
the blood-brain barrier), and bind antigens with high af-
finity. Several VHHs showing such activity have been de-
scribed so far; e.g. a VHH recognizing epidermal growth 
factor receptor (EGFR), an antigen overexpressed on the 
surface of many tumors, was shown to bind EGFR in biop-
sy samples and in vivo [6,29,39]. The main disadvantage of 
VHHs as imaging tools is their relatively high renal upta-
ke. The retention of VHHs in kidneys was shown to be de-
pendent on megalin, a receptor involved in re-absorption 
of proteins, but avenues are being explored to decrease in-
teractions with megalin-mediated VHH renal intake [28].
6.2.2. Diagnostics
VHHs have been shown to pass the blood-brain barrier, 
most probably by transcytosis [2]; however, due to their 
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ways to overcome this problem may be preparing multi-
valent (bivalent, pentavalent) VHHs, or fusing VHHs to 
human Fc fragments [42]. The latter seems to be a better 
option, since such protein has a longer half-life and bet-
ter tumor penetration ability. A VHH that can pass thro-
ugh the blood-brain barrier and can recognize oligomeric 
forms of amyloid b has been described; it was suggested 
that it can be used in diagnosis of Alzheimer’s disease [48].
VHHs can also be used for intracellular imaging: a VHH 
fused to green fluorescent protein (GFP), and called a chro-
mobody, can serve as an imaging tool if expressed in the 
intracellular compartment in cell lines [53,65].
6.2.3. Protein purification
An important application of VHHs may be purification of 
proteins by affinity chromatography. In fact, all procedu-
res using antibodies or their recombinant derivatives may 
be adapted to the use of VHHs, with all the advantages 
of VHHs such as easy expression and high thermostabi-
lity being preserved. Thus, VHHs can be an efficient tool 
for purification of proteins: a VHH recognizing GFP co-
uld serve as a tool for purification of GFP-fused proteins 
[64]. Another example is nitric oxide reductase, which was 
purified from a cell lysate membrane fraction using spe-
cific His-tagged VHHs and nickel affinity chromatogra-
phy [7]. A different approach was used for purification of 
the Duffy antigen receptor for chemokines (DARC) from 
DARC-expressing K562 cells. The anti-DARC VHHs were 
immobilized on the column using amine coupling chemi-
stry and cell lysate was applied. A peptide whose sequen-
ce is the same as the sequence recognized by VHH was 
used to elute the target protein, and the result was highly 
purified protein [71].
6.2.4. Enzymology
Recently, it was shown that the VHH library obtained 
after immunization with an enzyme can be used to obtain 
not only the anti-enzyme VHHs that can inhibit the enzy-
me, but also anti-idiotypic VHHs with catalytic activity. 
Thus, camel immunized with alliinase (S-alkyl-L-cysteine 
S-oxide alkyl-sulfenate-lyase) produced VHHs with allii-
nase activity which can convert the prodrug alliin into al-
licin [50]. It was also shown that such VHHs can signifi-
cantly suppress growth of B16 tumor cells in the presence 
of alliin in vitro [50].
7. Summary
VHHs, which are the smallest fully active antibody frag-
ments, can be a “coming of age” in medicine and biotech-
nology. Their unique features – small size, high affinity, abi-
lity to bind epitopes inaccessible for regular antibodies or 
their fragments, amazing stability, and feasibility of expres-
sion – suggest that they may be considered as a new magic 
bullet of medicine. In addition, they may be employed in 
biotechnology, therapy, imaging and laboratory practice.
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